Do drug package inserts meet the rules and regulations of Iran’s Food and Drug Administration in terms of informing patients?
Do drug package inserts meet the rules and regulations of Iran’s Food and Drug Administration in terms of informing patients?
نویسندگان: طاهره اعتراف اسکوئی , وحیده زارع , مسلم نجفی
کلمات کلیدی: Health communication,
Package inserts, Drug product,
Drug labeling, Neurologic,
Psychiatric, Medication
نشریه: 13461 , 3 , 9 , 2019
| نویسنده ثبت کننده مقاله |
وحیده زارع |
| مرحله جاری مقاله |
تایید نهایی |
| دانشکده/مرکز مربوطه |
دانشکده مدیریت و اطلاع رسانی پزشکی |
| کد مقاله |
68497 |
| عنوان فارسی مقاله |
Do drug package inserts meet the rules and regulations of Iran’s Food and Drug Administration in terms of informing patients? |
| عنوان لاتین مقاله |
Do drug package inserts meet the rules and regulations of Iran’s Food and Drug Administration in terms of informing patients? |
| ناشر |
4 |
| آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ |
خیر |
| عنوان نشریه (خارج از لیست فوق) |
|
| نوع مقاله |
Original Article |
| نحوه ایندکس شدن مقاله |
ایندکس شده سطح یک – ISI - Web of Science |
| آدرس لینک مقاله/ همایش در شبکه اینترنت |
|
| Abstract
Background: Drug package inserts (PIs) are the most accessible source of information for
users and are designed to aid the safe use of medicines and avert adverse events. This study
measured the conformity of PIs with the health communications standards of Iran’s Food and
Drug Administration (FDA).
Methods: This descriptive cross-sectional study evaluated 92 PIs related to 22 best-selling
neurological and psychiatric drugs in Iran based on criteria approved by Iran’s FDA. Six
categories of criteria were considered in evaluating the extent of conformity: I) writing and
formatting, II) references, III) drug description, IV) warnings and precautions, V) interactions,
and VI) side effects. Each PI was scored based on observation of standards; data was analyzed
using Microsoft Excel pivot tables.
Results: In total, 2929 items from 92 PIs were evaluated, of which 37 (40.2%) were related to
antidepressants, 31 (33.7%) to sedatives and hypnotics, and 24 (26%) to anticonvulsant drugs.
The PI content was insufficient in various aspects of conformity with standards in each category.
Among the six categories, the best match was found in warnings and precautions with 667
items (72.5%), followed by writing and formatting with 663 (69.1%). The lowest conformity was
found in the reference category with 194 (26.4%) items.
Conclusion: The PIs of Iranian neurological drugs do not fully meet Iran’s FDA standards. It is
strongly recommended that smart PIs be developed using mobile apps to overcome this problem. |
| نام فایل |
تاریخ درج فایل |
اندازه فایل |
دانلود |
| package inserts zarea eteraf 2019.pdf | 1398/05/26 | 292216 | دانلود |